There is no single number that captures life expectancy at stage 4 chronic kidney disease (CKD), because the range depends heavily on age, the underlying cause of kidney damage, cardiovascular health, and whether the disease is actively managed. Many people with stage 4 CKD live for years or even decades, while others face a much shorter timeline. The reason for this enormous spread is that kidney function alone is a poor predictor of survival: in most people diagnosed at this stage, especially older adults, the biggest threat to life is not kidney failure itself but heart disease and other conditions that travel alongside declining kidney function.
Why a Single Number Does Not Work
Stage 4 CKD means an estimated glomerular filtration rate (eGFR) between 15 and 29, roughly 15 to 29 percent of normal kidney filtering capacity. That sounds alarming, and it is serious, but it does not automatically mean a person is close to needing dialysis or transplant. A large UK cohort of over 30,000 people with stage 4 CKD (average age 77) found that only 18 percent progressed to kidney failure, while 53 percent died from other causes during follow-up. The combined risk of either dying or reaching kidney failure was about 64 percent at five years and 87 percent at ten years, but standard risk calculators that ignored the possibility of dying from something else consistently overestimated how many people would reach kidney failure, sometimes by nearly 20 percentage points at the ten-year mark.
1PubMed Central. Influence of Mortality on Estimating the Risk of Kidney Failure in People with Stage 4 CKDThat overestimation matters for patients trying to understand their future. Many people are told their kidneys are “on a path to failure” when, statistically, they are more likely to die of a heart attack or stroke than to ever need dialysis. This does not mean the kidney disease is harmless. It means the conversation about prognosis has to include the whole picture, not just the kidneys.
Age Is the Strongest Single Predictor
If one factor dominates the prognosis conversation, it is age. In younger adults with stage 4 CKD, the risk of eventually reaching kidney failure is higher than the risk of dying from another cause. That relationship reverses sharply with age. A Canadian study found that among people younger than 65, kidney failure was the more likely outcome. But by ages 75 to 84, the risk of death was roughly six times higher than the risk of kidney failure. In those 85 and older, death was about 25 times more likely than kidney failure.
2JAMA Network Open. Association of Age With Risk of Kidney Failure in Adults With Stage IV Chronic Kidney Disease in CanadaAn Australian cohort told a very similar story. For people under 65, the five-year risk of dying after a stage 4 diagnosis was about 18 percent, while the risk of reaching kidney failure was about 39 percent. By age 85 and above, the five-year death risk climbed to 78 percent, while the kidney failure risk dropped to roughly 1 percent.
3Medical Journal of Australia. Competing risks of death and kidney failure in Australian adults with stage 4 chronic kidney diseaseThe practical takeaway is that a 50-year-old and an 85-year-old diagnosed with the same eGFR face fundamentally different futures. For the younger patient, the priority is slowing kidney decline and preparing for potential dialysis or transplant. For the older patient, aggressive preparation for kidney replacement therapy may not improve survival and can reduce quality of life.
Cardiovascular Disease as the Leading Threat
Heart and blood vessel disease is the leading cause of death in people with advanced CKD, outranking kidney failure itself. The risk is already elevated in earlier stages, but it climbs steeply once kidney function drops into stage 4 and 5 territory.
4PubMed Central. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic OptionsThe link runs deeper than shared risk factors like high blood pressure and diabetes. Declining kidney function triggers a cascade of metabolic changes, including mineral and bone disorders that promote calcium deposits in blood vessel walls. This vascular calcification stiffens arteries and raises the risk of heart attack, stroke, and heart failure.
5PubMed. Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implicationsBecause cardiovascular disease is so dominant in this population, treatments that protect the heart often do as much or more for survival than treatments aimed solely at the kidneys. Blood pressure control, cholesterol management, and newer kidney-protective drugs that also happen to benefit the heart all contribute to a longer life at stage 4.
How Proteinuria Changes the Outlook
Two people can have identical eGFR values and very different prognoses depending on how much protein is leaking into their urine. Albuminuria, the presence of the protein albumin in urine, is an independent signal of kidney and cardiovascular damage. Research across both men and women has shown that life expectancy at any given eGFR level differs substantially based on whether albuminuria is present and how severe it is, with the effect being especially pronounced when eGFR is still above 30.
6PubMed Central. Kidney function, albuminuria and life expectancyProteinuria reflects ongoing damage to the kidney’s filtering units and is also a risk factor for faster decline toward kidney failure. A Japanese matched-cohort study found that people with proteinuria lost significantly more years of life across all age groups compared to those without it, even when their kidney filtering rates were similar.
7Preventive Medicine Reports. Mortality risk and years of life lost for people with reduced renal function detected from regular health checkup: A matched cohort studyRisk calculators used to predict kidney failure progression perform better once they include a urine albumin-to-creatinine ratio (ACR) measurement alongside eGFR and age. Adding ACR to a basic three-variable model meaningfully improves how accurately the calculator sorts patients into higher and lower risk groups. Tacking on additional lab markers beyond ACR offers only a small further improvement.
8PubMed Central. Real world evaluation of kidney failure risk equations in predicting progression from chronic kidney disease to kidney failure in an Australian cohortDiabetes and the Underlying Cause of Kidney Disease
The disease that caused the kidney damage in the first place also shapes survival. Diabetic kidney disease carries a worse prognosis than most other causes. A large Italian registry study spanning 13 years found that ten-year survival was significantly lower in patients with type 2 diabetes compared to those without it (roughly 23 percent versus 36 percent). After adjusting for age, sex, baseline kidney function, and cardiovascular comorbidities, diabetes remained an independent risk factor for death.
9Nephrology Dialysis Transplantation. P0692NON-PROTEINURIC DIABETIC NEPHROPATHY AND THE RISK OF MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD)The reason is partly biological and partly statistical. Diabetes accelerates vascular damage throughout the body. People with diabetic kidney disease tend to accumulate more cardiovascular events before and after entering specialized kidney care programs, and they start dialysis less frequently, likely because they die from cardiovascular causes first.
Medications That Can Slow Progression
Several classes of drugs have shown the ability to slow kidney function decline in stage 4 CKD, which translates to delaying or avoiding dialysis and potentially extending life.
SGLT2 inhibitors (originally developed for diabetes) have become a cornerstone of kidney protection. In a subgroup analysis of the DAPA-CKD trial, patients with stage 4 CKD who received dapagliflozin experienced a 27 percent reduction in the combined risk of kidney failure, cardiovascular events, and death compared to placebo. Their rate of kidney function decline was also slower: eGFR dropped by about 2.15 per year in the treatment group versus 3.38 per year with placebo.
10PubMed Central. Effects of Dapagliflozin in Stage 4 Chronic Kidney DiseaseFinerenone, a newer type of mineralocorticoid receptor antagonist, has shown kidney and cardiovascular benefits specifically in people with type 2 diabetes and CKD. In the FIDELIO trial, a composite kidney outcome occurred in about 18 percent of those on finerenone versus 21 percent on placebo over a median follow-up of 2.6 years.
11PubMed. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes A subgroup analysis focusing on stage 4 CKD patients showed a trend toward reduced cardiovascular events and consistently lower proteinuria, though results were less stable over longer follow-up periods.12PubMed Central. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis
Older blood pressure drugs known as RAS inhibitors (ACE inhibitors and ARBs) have long been standard in CKD management. A common concern is whether they should be stopped as kidney function gets very low, since they can temporarily lower eGFR further. The STOP-ACEi trial addressed this directly: discontinuing these drugs in advanced CKD did not lead to a meaningful improvement in kidney function at three years. In fact, patients who stopped their RAS inhibitor were somewhat more likely to reach kidney failure than those who continued, though the difference did not quite reach statistical significance.
13PubMed. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney DiseaseDiet and Acid-Base Balance
Dietary management is one of the areas where patients often feel they can exert some control. The evidence, however, is more nuanced than popular advice suggests. A Cochrane review of low-protein diets found that a moderately reduced protein intake probably made little difference in the number of people who progressed to end-stage kidney disease compared to a normal protein diet. Very low protein diets (typically supplemented with special amino acid preparations) did appear to reduce progression, but neither approach had a clear effect on death rates.
14PubMed Central. Low protein diets for non-diabetic adults with chronic kidney diseaseA more recent observational study from Italy offered a more optimistic picture for patients who received personalized dietary counseling and stuck with it. Those who adhered to a tailored low-protein diet saw a much slower rate of kidney function decline and a dramatically lower rate of dialysis initiation and death compared to non-adherent patients.
15Clinical Kidney Journal. Low protein diet with personalized support in advanced chronic kidney disease: association with disease progression, dialysis delay and mortality The caveat is that observational studies cannot prove the diet caused the improvement; people who follow medical advice closely tend to be healthier in ways that are hard to measure.
Metabolic acidosis, a buildup of acid in the blood, is common in stage 4 CKD and may accelerate kidney decline. Oral sodium bicarbonate supplements can correct this. A meta-analysis found that bicarbonate therapy slowed the rate of eGFR loss and roughly halved the risk of reaching end-stage kidney failure, though the evidence was rated as low certainty.
16Kidney International Reports. A Systematic Review and Meta-Analysis on Effects of Bicarbonate Therapy on Kidney Outcomes Interestingly, a small trial found that increasing fruit and vegetable intake (which has an alkalizing effect on blood chemistry) achieved similar benefits to bicarbonate supplements in stage 4 CKD, suggesting that dietary approaches can help without adding yet another pill.17PubMed Central. A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate
Complications That Shorten Life
Stage 4 CKD rarely comes alone. Several complications accumulate as kidney function drops, and each one independently worsens the outlook.
Anemia is extremely common because the kidneys produce less erythropoietin, the hormone that signals red blood cell production. Multiple large studies have linked anemia in CKD to a higher risk of heart failure, hospitalization, and death.
18Kidney Medicine. Iron-Deficiency Anemia in CKD: A Narrative Review for the Kidney Care TeamHigh potassium (hyperkalemia) is another frequent concern, because the kidneys can no longer excrete potassium efficiently. It can cause dangerous heart rhythm disturbances. Newer potassium-binding drugs like patiromer and sodium zirconium cyclosilicate have proven effective at keeping potassium in the normal range, and they may allow patients to remain on kidney-protective medications like RAS inhibitors and finerenone that can themselves raise potassium.
19Mayo Clinic Proceedings. Management of Hyperkalemia in Patients with Chronic Kidney DiseaseMineral and bone disorders, driven by disrupted calcium, phosphorus, and vitamin D metabolism, contribute to the vascular calcification discussed earlier. The net effect is stiffer, more fragile arteries and weaker bones, a combination that raises both cardiovascular death risk and fracture risk simultaneously.
5PubMed. Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implicationsDialysis Versus Conservative Care in Older Adults
For younger patients whose kidneys continue to decline, dialysis or transplantation eventually becomes a lifeline. But the calculus changes for elderly patients. A UK study comparing dialysis with conservative management in patients older than 75 found that those without heavy comorbidity burdens gained about seven extra months of median survival with dialysis (roughly 37 versus 29 months). For those with high comorbidity, the survival difference shrank to about five months and was not statistically significant.
20Nephrology Dialysis Transplantation. Survival of elderly patients with stage 5 CKD: comparison of conservative management and renal replacement therapyA German survival analysis painted an even more striking picture. While dialysis patients had a lower initial death rate, that advantage faded quickly. In elderly patients, the survival benefit of dialysis over conservative care disappeared within about two to three months, after which the two groups had similar hazard rates. For the very elderly (around age 95), the advantage lasted roughly one month.
21PubMed Central. Survival analysis of conservative vs. dialysis treatment of elderly patients with CKD stage 5These findings do not mean dialysis is useless for older adults. They mean that the decision has to weigh quality of life, not just months of survival. Dialysis involves multiple sessions per week, dietary restrictions, vascular access procedures, and frequent hospital visits. For some patients, those trade-offs are worth it. For others, a conservative approach focused on symptom control and comfort allows more time at home with less medical burden.
The Symptom Burden at Advanced Stages
One finding that surprises many patients and families is that the symptom burden in advanced CKD is comparable to what people experience once they are already on dialysis. A study enrolling 87 patients with advanced CKD and 90 on dialysis found no significant difference in the total number of symptoms, symptom severity scores, depression rates, or quality-of-life measures between the two groups.
22PubMed Central. Symptom burden, depression, and quality of life in chronic and end-stage kidney diseaseFatigue, pain, sleep disturbance, and low mood are common at stage 4 and do not necessarily improve with dialysis. Recognizing this early matters because it shifts the management focus. If a patient’s quality of life is already poor from these symptoms, starting dialysis may not relieve them. Addressing fatigue through anemia treatment, depression through screening and therapy, and sleep through targeted interventions can make a larger practical difference in daily life than many patients expect.
Why Early Referral to a Kidney Specialist Matters
One of the most consistent findings in the CKD literature is that patients referred to a nephrologist early in their disease course do better than those referred late. A Korean prospective study compared patients referred to nephrology more than a year before needing dialysis with those referred later. After two years, late-referral patients had more than double the risk of death. The gap was even wider in patients with diabetic kidney disease, where late referral was linked to nearly five times the mortality risk.
23PubMed Central. Early referral to a nephrologist improved patient survival: prospective cohort study for end-stage renal disease in KoreaEarly specialist care matters because it allows time to optimize blood pressure, introduce kidney-protective medications, manage complications like anemia and acidosis, and plan for the future, whether that means dialysis preparation, transplant evaluation, or a shared decision to pursue conservative management. Patients who arrive at a nephrologist’s office in crisis, already at the doorstep of kidney failure, miss the window for many of these interventions.
Ethnicity and Risk Prediction
Risk prediction tools do not perform identically across all ethnic groups. An external validation study testing the Kidney Failure Risk Equation in a South Asian population found that the risk of needing kidney replacement therapy differed by ethnicity, and the model’s accuracy improved when ethnicity and its interactions with kidney markers were incorporated. Accounting for the competing risk of death further refined the predictions.
24Nephrology Dialysis Transplantation. #5522 USING THE KIDNEY FAILURE RISK EQUATION TO PREDICT END-STAGE KIDNEY DISEASE IN CKD PATIENTS OF SOUTH ASIAN ETHNICITY: AN EXTERNAL VALIDATION STUDYAmong dialysis patients in the United States, a large study of over 1.3 million people found that Black patients, after adjusting for demographics and comorbidities, actually had a lower risk of death on dialysis than white patients. The reasons are debated but may include differences in the types of kidney disease that lead to dialysis, age at disease onset, and physiological responses to dialysis itself.
25JAMA. Association of Race and Age With Survival Among Patients Undergoing DialysisThese patterns highlight that population-level statistics can be misleading when applied to an individual. The best available tools combine kidney function, proteinuria, age, and clinical context to generate a personalized estimate. Your nephrologist can run a validated risk calculator using your specific lab values, and that number will be far more meaningful than any general statistic about stage 4 CKD as a whole.